
|Articles|February 6, 2023
Bristol Myers Squibb Launch New DTC Campaign in Plaque Psoriasis
BMS launched a new direct-to-consumer (DTC) campaign for SOTYKTU™ (deucravacitinib) for the plaque psoriasis community.
Advertisement
The campaign, “Found It,” is part of a robust DTC program designed to educate adults with moderate to severe plaque psoriasis about SOTYKTU™, a new oral treatment option.
The first TV spot, which aired on Sunday, February 5th during the 65th annual Grammy Awards, celebrates the feeling of finally finding a treatment that may restore confidence and freedom and, most importantly, the ability to love your skin.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement





Actionable Insights at the Point of Care: A New Era in Provider Engagement
Published: | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya
4
FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria
5
